RK checklist

orted	Reported on Page Number/Line Number	Repo Secti
N		
marker examined, the study objectives, and any pre-specified hypotheses.	Page 3, Line 75-79	Introdu
D METHODS		
the characteristics (e.g., disease stage or co-morbidities) of the study patients, including their source and inclusion and exclusion	Page 4, Line82-87	Method
treatments received and how chosen (e.g., randomized or rule-based).	-	-
cteristics		
type of biological material used (including control samples) and methods of preservation and storage.	Page 5, Line124-126	Method
he assay method used and provide (or reference) a detailed protocol, including specific reagents or kits used, quality control es, reproducibility assessments, quantitation methods, and scoring and reporting protocols. Specify whether and how assays were d blinded to the study endpoint.	Page 5, Line126-133	Method
method of case selection, including whether prospective or retrospective and whether stratification or matching (e.g., by stage of or age) was used. Specify the time period from which cases were taken, the end of the follow-up period, and the median follow-up	Page 4, Line82	Method
define all clinical endpoints examined.	-	-
ndidate variables initially examined or considered for inclusion in models.	Page 4, Line89-90 Table 1	Method
onale for sample size; if the study was designed to detect a specified effect size, give the target power and effect size.	Page 4, Line82	Method
is methods		
ll statistical methods, including details of any variable selection procedures and other model-building issues, how model ons were verified, and how missing data were handled.	Page 4, Line89-108 Page 5, Line109-134 Page 6, Line135-140	Method
w marker values were handled in the analyses; if relevant, describe methods used for cutpoint determination.	-	-

the flow of patients through the study, including the number of patients included in each stage of the analysis (a diagram may ul) and reasons for dropout. Specifically, both overall and for each subgroup extensively examined report the numbers of and the number of events.	Page 6, Line145-146	Results
stributions of basic demographic characteristics (at least age and sex), standard (disease-specific) prognostic variables, and rker, including numbers of missing values.	Table 1	-
sentation		
relation of the marker to standard prognostic variables.	Figure 2	-
nivariable analyses showing the relation between the marker and outcome, with the estimated effect (e.g., hazard ratio and robability). Preferably provide similar analyses for all other variables being analyzed. For the effect of a tumor marker on a vent outcome, a Kaplan-Meier plot is recommended.	Figure 2; Figure 3	
ultivariable analyses, report estimated effects (e.g., hazard ratio) with confidence intervals for the marker and, at least for the el, all other variables in the model.	Page 7, Line179-183	Results
eported results, provide estimated effects with confidence intervals from an analysis in which the marker and standard c variables are included, regardless of their statistical significance.	Table 3	
eport results of further investigations, such as checking assumptions, sensitivity analyses, and internal validation.	Page 7, Line172-174	Results
the results in the context of the pre-specified hypotheses and other relevant studies; include a discussion of limitations of the	Page 9, Line231-239 Page 10, Line246-248 Page 10,Line266-267 Page 11, Line268-269 Page 12, Line299-301	Discuss Discuss Discuss Discuss Discuss
mplications for future research and clinical value.	Page 11, Line294-295 Page 12,,Line 296,Line 303-306	Discuss Conclus

M, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;

on: https://dx.doi.org/10.21037/atm-21-6576